Most Read Articles
Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
3 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Charlson Comorbidity Index a valuable tool in estimating renal cell carcinoma prognosis

13 Aug 2020

Use of the Charlson Comorbidity Index (CCI) appears to be beneficial for assessing prognosis and optimizing therapy in patients with advanced renal cell carcinoma who are receiving first-line sunitinib or pazopanib, suggests a recent study.

Of the 102 patients included, 64 received first-line sunitinib and 38 pazopanib. Forty-two patients (41.9 percent) had a CCI of ≥9. Dose-limiting toxicities occurred more frequently in those with CCI ≥9 (69 percent vs 40 percent; p=0.004). CCI was independently associated with dose-limiting toxicity (hazard ratio [HR], 4.30; p=0.002).

After adjusting for other variables, it was found that CCI ≥9 was also a significant prognostic factor for progression-free (HR, 1.76; p=0.02) and overall survival (HR, 1.75; p=0.03).

In this study, the investigators retrospectively examined the files of locally advanced and metastatic renal cell carcinoma patients, who received first-line sunitinib or pazopanib, and calculated the CCI for each participant. Patients were then stratified into Memorial Sloan-Kettering Cancer Center risk groups.

Binomial logistic regression analysis was conducted to evaluate the predictors of dose-limiting toxicity, and univariate and multivariate Cox regression models were generated to determine the prognostic factors for survival.

“Antiangiogenic tyrosine kinase inhibitors, sunitinib and pazopanib, have proven efficacy in advanced renal cell carcinoma, with specific adverse events occurring during treatment process,” the investigators said. “Comorbidities can reflect functional status and have prognostic value in oncology patients.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
3 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.